AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14729745
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg every 12 h (n = 215)
Trial: 7967317
Drug: SM (streptomycin)
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM (streptomycin) twice weekly for 6 months in addition to INH and RFP for 9 months (S2 group)
Trial: 21158908
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day plus Melatonin 3 mg
Trial: 21158908
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day plus Melatonin 5 mg
Trial: 17880560
Drug: Subcutaneous histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous histamine (1-10 ng twice a week; n = 46)
Trial: 17880560
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium valproate (500 mg daily dose; n = 46)
Trial: 3631681
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (dapsone and antivenom)
Trial: 30680975
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (LABA-LAMA-ICS) - vilanterol 25 µg/umeclidinium 62.5 µg/fluticasone furoate 100 µg
Trial: 30680975
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (LABA-ICS or LABA-LAMA)
Trial: 19589164
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment for malaria (IPTp) using sulfadoxine-pyrimethamine (SP)
Trial: 9576446
Drug: Cisapride 20
RxNorm normalized name: cisapride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 20 mg b.i.d.
Trial: 26474679
Drug: Fluticasone propionate/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/formoterol 500/20 μg b.i.d.
Trial: 26474679
Drug: Fluticasone propionate/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/formoterol 100/10 μg b.i.d.
Trial: 21310551
Drug: Dronabinol 20mg
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol 20mg twice a day
Trial: 12755528
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 50 microg every 4 h
Trial: 10868559
Drug: E2/NETA 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/NETA 1 mg
Trial: 3745524
Drug: Increasing concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing concentrations of anthralin (0.3%, 1%, 3%) for patients who failed to respond to UVB therapy
Trial: 26954876
Drug: Oral dyclonine
RxNorm normalized name: DYCLONINE
DrugBank: Dyclonine (DB00645)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dyclonine hydrochloride mucilage (ODHM)
Trial: 26954876
Drug: Tetracaine spray
RxNorm normalized name: benzocaine / butamben / tetracaine Mucosal Spray [Cetacaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine spray (TS)
Trial: 25019119
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with occlusal splint and analgesic and muscle relaxant medication (Group A)
Trial: 25019119
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group C) - patients who refused treatment
Trial: 18508951
Drug: Midostaurin 25
RxNorm normalized name: midostaurin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin 25 mg bid
Trial: 18508951
Drug: Midostaurin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin 50 mg bid
Trial: 18508951
Drug: Midostaurin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin 75 mg bid
Trial: 18508951
Drug: Midostaurin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin 75 mg tid
Trial: 18508951
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 100 mg dose
Trial: 18508951
Drug: Midostaurin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin 50 to 225 mg/day
Trial: 15910012
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg before MDMA 100 mg
Trial: 15910012
Drug: Placebo before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before MDMA 100 mg
Trial: 10887306
Drug: Salbutamol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (100 microgram, 2 puffs 4 times daily)
Trial: 14621753
Drug: Sequential course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential course of 14 days conventional immunosuppression (ALG, azathioprine, steroids) followed by cyclosporine and steroids
Trial: 14621753
Drug: Conventional immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunosuppression for 2 days followed by cyclosporine and steroids
Trial: 27036555
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (PPI) lansoprazole
Trial: 16082736
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment (peginterferon monotherapy for 48 weeks or shorter combination therapy for 24 weeks for RVR; triple therapy with histamine for 48 weeks or prolonged combination therapy for 72 weeks for SPR; triple therapy for FPR; high-dose peginterferon (360 microg/week) plus ribavirin for NUR)
Trial: 16082736
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (peginterferon alfa-2a 180 microg/week and ribavirin 1000-1200 mg/day)
Trial: 16082736
Drug: Histamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine (1 mg/day) in addition to peginterferon and ribavirin
Trial: 16082736
Drug: High-dose peginterferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose peginterferon (360 microg/week) plus ribavirin
Trial: 7952988
Drug: Combined chlorpromazine
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined chlorpromazine (600 mg daily) and electroconvulsive therapy (ECT)
Trial: 3555510
Drug: Methotrexate (MTX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (MTX), 10 mg/week, orally
Trial: 3555510
Drug: Azathioprine (AZA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (AZA), 100 mg/day, orally
Trial: 2294126
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human GH (hGH) at a dose of 1 IU/kg.week
Trial: 2294126
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human GH (hGH) at a dose of 1 IU/kg.week + 25 ng/kg.day ethinyl estradiol (E2)
Trial: 1100683
Drug: 1% chlorhexidine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine-containing gel used once a day for 4 weeks
Trial: 1100683
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel used during control period for 4 weeks
Trial: 1100683
Drug: Standardized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized oral hygiene instruction for 12 subjects
Trial: 31940591
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo Treg depletion (IVTRD) with basiliximab 20 mg IV on day +1 post-ASCT
Trial: 29871195
Drug: Intratympanic gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic gentamicin (ITG), 1 ml of gentamicin sulfate (40 g/L) buffered with 0.5 ml of sodium bicarbonate, administered weekly for 2 times
Trial: 29871195
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone (ITD), 5 mg for the first two days, then weekly for 4 weeks
Trial: 26013113
Drug: Herbal drug
RxNorm normalized name: herbal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal drug combination (Sinupret® extract Dragees) - daily dosage 3 × 160 mg
Trial: 26013113
Drug: Herbal drug
RxNorm normalized name: herbal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal drug combination (Sinupret® extract Dragees)
Trial: 23812875
Drug: IDegSimple (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDegSimple (once-daily insulin degludec with simple titration algorithm)
Trial: 23812875
Drug: IDegStep-wise (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDegStep-wise (once-daily insulin degludec with step-wise titration algorithm)
Trial: 22303704
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin calcium (LMWHC) combined with Yinxing Damo Injection (YDI)
Trial: 22303704
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin calcium (LMWHC)
Trial: 22303704
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin calcium (LMWHC) combined with YDI
Trial: 2963644
Drug: 0.02 mg
RxNorm normalized name: escin 0.02 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg (0.04 mg) controlled dosage aerosol
Trial: 2963644
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg ipratropium bromide (ITB)
Trial: 2963644
Drug: Intravenous doses
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous doses between 0.25 mg and 0.5 mg ITB
Trial: 30224391
Drug: 8-week group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week group-based cognitive remediation therapy (CRT)
Trial: 30658632
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements
Trial: 24671165
Drug: A‐CHESS smartphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A‐CHESS smartphone application (treatment as usual plus A‐CHESS)
Trial: 19887503
Drug: Candesartan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (4 to 16 mg daily)
Trial: 3117447
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of insulin and GRF
Trial: 31420292
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone at home
Trial: 31420292
Drug: Intravenous flucloxacillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous flucloxacillin in hospital
Trial: 25837194
Drug: Perineural injection
RxNorm normalized name: ROPIVACAINE HYDROCHLORIDE 2 mg in 1 mL PERINEURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineural injection (PN)
Trial: 24165382
Drug: LT vaccine
RxNorm normalized name: hepatitis A adult vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT vaccine
Trial: 21574174
Drug: 45 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg/day vitamin K2
Trial: 21574174
Drug: 90 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg/day vitamin K2
Trial: 1467095
Drug: Extradural infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extradural infusion of 0.15% bupivacaine with 0.01% diamorphine
Trial: 1467095
Drug: Extradural bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural bolus diamorphine 3.6 mg
Trial: 1467095
Drug: Patient-controlled i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled i.v. administration of diamorphine at a maximum rate of 1 mg per 5 min
Trial: 6379507
Drug: Bovine brain
RxNorm normalized name: bovine brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine brain gangliosides, 40 mg daily intramuscular injections for 6 months
Trial: 16372814
Drug: Dexamethasone-cyclophosphamide (D/C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone-cyclophosphamide (D/C) pulse therapy
Trial: 16372814
Drug: Methylprednisolone-azathioprine (M/A)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methylprednisolone-azathioprine (M/A) therapy
Trial: 9485967
Drug: Bupivacaine 0.0625%
RxNorm normalized name: BUPIVACAINE 0.0625%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.0625% with fentanyl 2.5 micrograms.ml‐1 at a rate of 10‐12 ml.h‐1
Trial: 2166716
Drug: Soluble dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble dietary fibre supplement (7 g/day for 2 weeks)
Trial: 7106067
Drug: 233 μg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 233 μg/m3 sulfuric acid
Trial: 7106067
Drug: 418 μg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 418 μg/m3 sulfuric acid
Trial: 7106067
Drug: 939 μg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 939 μg/m3 sulfuric acid
Trial: 26963842
Drug: Brexpiprazole 3
RxNorm normalized name: brexpiprazole 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole 3 mg/day
Trial: 25206295
Drug: Probiotic combination
RxNorm normalized name: PROBIOTIC COMBINATION CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic combination (Lactobacillus acidophilus ATCC 700396 and Bifidobacterium lactis ATCC SD5220)
Trial: 20397080
Drug: 6% Cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% Cellulose Sulfate microbicide gel
Trial: 17917625
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of prednisolone for 6 weeks followed by topical application of 2% minoxidil for 14 weeks
Trial: 17917625
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of prednisolone and minoxidil
Trial: 16086923
Drug: TnT-positive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TnT-positive group (TnT > or = 0.1 ng/mL)
Trial: 16086923
Drug: TnT-positive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TnT-positive group (TnT > or = 0.03 ng/mL)
Trial: 16086923
Drug: TnT-positive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TnT-positive group (TnT > or = 0.01 ng/mL)
Trial: 12161826
Drug: Center-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Center-based exercise (endurance, strength, balance, flexibility) 3 times weekly for months 1 to 6, once weekly for months 7 to 12 with home exercise 2 sessions a week, and at home only for months 13 to 18
Trial: 10444056
Drug: 0.3% topical
RxNorm normalized name: ZORYVE 0.3% Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 3 hours (Group A)
Trial: 10444056
Drug: 0.3% topical
RxNorm normalized name: ZORYVE 0.3% Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 5-6 hours (Group B)
Trial: 10444056
Drug: 0.3% topical
RxNorm normalized name: ZORYVE 0.3% Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% topical ciprofloxacin presoaked in disposable soft contact lenses for 10-12 hours, applied for 8-12 hours (Group C)
Trial: 2399774
Drug: Surgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery and chemotherapy (combination of bleomycin, vincristine, mitomycin-C, and cisplatin; later carboplatin and bleomycin)
Trial: 7365120
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of brain wave stimulator and concentration exercise
Trial: 25997818
Drug: Ganetespib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganetespib (150 mg/m² on days 1 and 15) in combination with Docetaxel (75 mg/m² on day 1)
Trial: 25997818
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m² on day 1) alone
Trial: 23245197
Drug: Contingency Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency Management (CM) treatment
Trial: 15552197
Drug: Topical NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical NSAIDs for three days preoperatively
Trial: 9609411
Drug: ATIII (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATIII (total dose 24000 units)
Trial: 367043
Drug: Clonidine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.05 mg twice daily
Trial: 367043
Drug: Tyramine 125
RxNorm normalized name: tyramine
DrugBank: Tyramine (DB08841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyramine 125 mg
Trial: 30783069
Drug: Internet-based Cognitive-Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based Cognitive-Behavioural Therapy (iCBT), 8-week therapist-guided
Trial: 26446153
Drug: Interactive training
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive training sessions for nursing staff (two 4-hour sessions) to recognize potentially harmful medications
Trial: 21826782
Drug: Transfusions and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusions and chelation (standard therapy)
Trial: 17229772
Drug: Venlafaxine 37.5
RxNorm normalized name: venlafaxine 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 37.5 mg twice a day for 4 weeks
Trial: 17229772
Drug: Clonidine 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.075 mg twice a day for 4 weeks
Trial: 7930697
Drug: RT-PCR assay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT-PCR assay for MCV RNA on PBMC RNA preparations
Trial: 30418116
Drug: Medical Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Cannabis Therapy (MCT) after 3 months of Standardised Analgesic Therapy (SAT)
Trial: 30418116
Drug: Medical Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Cannabis Therapy (MCT)
Trial: 30418116
Drug: Standardised Analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised Analgesic Therapy (SAT)
Trial: 25968836
Drug: Intravaginal DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal DHEA (6.5 mg daily for 52 weeks)
Trial: 19779467
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1,500 mg per day)
Trial: 16540815
Drug: quetiapine (400‐600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quetiapine (400‐600 mg/day)
Trial: 16540815
Drug: divalproex (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: divalproex (serum level 80‐120 microg/mL)
Trial: 3936908
Drug: Oral L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-carnitine supplementation (70 mumol/l/kg/24 h in 24 mL of 5% dextrose) for seven days
Trial: 3936908
Drug: Placebo supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplementation (dextrose 5%, 24 cc/24 h) for seven days
Trial: 31079938
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg plus bevacizumab 15 mg/kg intravenously once every 3 weeks
Trial: 31079938
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg orally once daily for 4 weeks on, 2 weeks off
Trial: 25122645
Drug: 0.25, 0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25, 0.5, and 1.0 L of milk
Trial: 22425473
Drug: Standard social
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard social cognitive rehabilitation treatment, n=24
Trial: 12456597
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or no treatment (Control)
Trial: 8324872
Drug: Epirubicin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 75 mg/m2
Trial: 8648369
Drug: Epirubicin 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 90 mg/m2
Trial: 8612318
Drug: Epirubicin 105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 105 mg/m2
Trial: 8324872
Drug: Epirubicin 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 120 mg/m2
Trial: 2007742
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Beclomethasone dipropionate (BD) enemas for 28 days
Trial: 2007742
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Betamethasone phosphate (BP) enemas for 28 days